A Retrospective Cohort Study on the Risk of Kidney Disease in HIV Positive Individuals Receiving Tenofovir Based Regimens

被引:0
|
作者
Khandelia, Vikash [1 ]
Nama, Umashankar [1 ]
Mahavar, Ashok [1 ]
Rathore, Anjali [1 ]
机构
[1] Govt Med Coll & Hosp, Dept Nephrol, Kota, Rajasthan, India
关键词
Acquired immunodeficiency syndrome; Antiretroviral therapy; Chronic kidney disease; Nephrotoxicity; ANTIRETROVIRAL THERAPY; RENAL DYSFUNCTION; IMPAIRMENT; PREVALENCE;
D O I
10.7860/JCDR/2022/50272.16425
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Exposure to Tenofovir often leads to the development of some irreversible high risk for kidney disease events. In Human Immunodeficiency Virus (HIV) patients, the prolonged treatment with tenofovir use frequently causes mildto-moderate nephrotoxicity. Hence, there is a need to further investigate the efficacy and the adverse effects associated with tenofovir use to combat the decreased morbidity and mortality associated with the declined kidney function. Aim: To investigate the risk of kidney disease associated with tenofovir use. Materials and Methods: A retrospective study was conducted at the tertiary care centre in northern India, from August 2009 to January 2017 and analysed during January to May 2021. The patients with HIV infection who were administered Tenofovir, Lamivudine and Efavirenz (TLE) and Zidovudine, Lamivudine and Nevirapine (ZLN) were included.The patients were divided into two group based on the TLE and ZLN regimen they received. These patients were on a regular follow-up for six months. The data was assessed on the basis of serum creatinine and estimated Glomerular Filtration Rate ( eGFR) (using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation), body weight and Cluster of Differentiation (CD4) count. Results: Out of 703 patients, 364 patients were administered with TLE, while 339 patients received ZLN. In both the groups, the number of patients were between the age 21-40 years was significantly higher, followed by patients between the age 4160 years. The mean weight and CD4 count of the patients in both the groups significantly increased with the progression of time (p<0.001). The creatinine levels at baseline and at 24 months were comparable in both the groups, p>0.05. The mean eGFR level was significantly lowered in TLE group (112.2 mL/ min/ 1.73 m(2)) compared to ZLN group (123.5 mL/ min/1.73m(2)) at 24-months follow-up (p<0.001). Conclusion: Overall results demonstrate that increasing exposure to tenofovir was associated with a higher incidence of CKD. The serum creatinine levels were comparable between the TLE and ZLN group.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study
    Thuppal, Sowmyanarayanan V.
    Wanke, Christine A.
    Noubary, Farzad
    Cohen, Joshua T.
    Mwamburi, Mkaya
    Ooriapdickal, Abraham C.
    Muliyil, Jayaprakash
    Kang, Gagandeep
    Varghese, George M.
    Rupali, Priscilla
    Karthik, Rajiv
    Sathasivam, Rajkumar
    Clarance, Peace
    Pulimood, Susanne A.
    Peter, Dincy
    George, Leni
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2015, 109 (06) : 379 - 385
  • [2] A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans
    Scherzer, Rebecca
    Gandhi, Monica
    Estrella, Michelle M.
    Tien, Phyllis C.
    Deeks, Steven G.
    Grunfeld, Carl
    Peralta, Carmen A.
    Shlipak, Michael G.
    AIDS, 2014, 28 (09) : 1289 - 1295
  • [3] Determinants and Incidence of Chronic Kidney Disease with Tenofovir-Based Antiretroviral Therapy Regimens: A Cohort Study in HIV-Infected Adults in South China
    Liu, Fang
    Wang, Yi
    Liu, Hong
    Chen, Chen
    Miao, Liang-Bin
    Li, Zhao-Yi
    Wang, Miao-Chan
    Huang, Jin-Song
    Bao, Jian-Feng
    CURRENT HIV RESEARCH, 2022, 20 (03) : 242 - 250
  • [4] Risk of chronic kidney disease in individuals on lithium therapy in Iceland: a nationwide retrospective cohort study
    Gislason, Gisli
    Indridason, Olafur S.
    Sigurdsson, Engilbert
    Palsson, Runolfur
    LANCET PSYCHIATRY, 2024, 11 (12): : 1002 - 1011
  • [5] Non-Viral Liver Disease Burden In HIV Positive Individuals: An Observational Retrospective Cohort Study
    Shur, Natalie
    Fisher, Martin
    Gilleece, Yvonne
    Verma, Sumita
    HEPATOLOGY, 2014, 60 : 595A - 595A
  • [6] Retrospective review of ART regimens in HIV-positive to HIV-positive kidney transplant recipients
    Barday, Zunaid
    Manning, Kathryn
    Freercks, Robert
    Bertels, Laurie
    Wearne, Nicola
    Muller, Elmi
    TRANSPLANTATION, 2024, 108 (09) : 236 - 236
  • [7] Retrospective Review of ART Regimens in HIV-Positive to HIV-Positive Kidney Transplant Recipients
    Barday, Zunaid
    Manning, Kathryn
    Freercks, Robert
    Bertels, Laurie
    Wearne, Nicola
    Muller, Elmi
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (09): : 2039 - 2046
  • [8] Prevalence and risk factors of chronic kidney disease in an HIV positive Mexican cohort
    Verónica Valdivia-Cerda
    Monserrat Alvarez-Zavala
    Karina Sánchez-Reyes
    Rodolfo I. Cabrera-Silva
    Vida V. Ruiz-Herrera
    Aldo D. Loza-Salazar
    Pedro Martínez-Ayala
    Juan C. Vázquez-Limón
    Guillermo García-García
    Jaime F. Andrade-Villanueva
    Luz A. González-Hernández
    BMC Nephrology, 22
  • [9] Prevalence and risk factors of chronic kidney disease in an HIV positive Mexican cohort
    Valdivia-Cerda, Veronica
    Alvarez-Zavala, Monserrat
    Sanchez-Reyes, Karina
    Cabrera-Silva, Rodolfo, I
    Ruiz-Herrera, Vida V.
    Loza-Salazar, Aldo D.
    Martinez-Ayala, Pedro
    Vazquez-Limon, Juan C.
    Garcia-Garcia, Guillermo
    Andrade-Villanueva, Jaime F.
    Gonzalez-Hernandez, Luz A.
    BMC NEPHROLOGY, 2021, 22 (01)
  • [10] Association of tenofovir exposure with kidney disease risk in HIV infection
    Scherzer, Rebecca
    Estrella, Michelle
    Li, Yongmei
    Choi, Andy I.
    Deeks, Steven G.
    Grunfeld, Carl
    Shlipak, Michael G.
    AIDS, 2012, 26 (07) : 867 - 875